Safety And Efficacy Of Inc280 In Combination With Gefitinib (Gef) In Patients With Egfr-Mutated (Mut), Met-Positive Nsclc: A Single-Arm Phase Ib/Ii Study.
JOURNAL OF CLINICAL ONCOLOGY（2014）
摘要
8017 Background: Despite high response rates to EGFR tyrosine kinase inhibitors (TKIs), most patients (pts) with EGFR-mut NSCLC ultimately relapse. Dysregulation of the MET pathway is implicated as...
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要